{"id":"acalabrutinib-treatment-c","safety":{"commonSideEffects":[{"rate":"22%","effect":"Headache"},{"rate":"21%","effect":"Diarrhea"},{"rate":"17%","effect":"Nausea"},{"rate":"16%","effect":"Fatigue"},{"rate":"14%","effect":"Cough"}]},"_chembl":{"chemblId":"CHEMBL4747506","moleculeType":"Unknown","molecularWeight":"465.52"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Acalabrutinib is a small molecule inhibitor of Bruton's tyrosine kinase (BTK), a key component in the B-cell receptor signaling pathway.","oneSentence":"BTK inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:32:39.950Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic lymphocytic leukemia"},{"name":"Mantle cell lymphoma"}]},"trialDetails":[{"nctId":"NCT04115631","phase":"PHASE2","title":"A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-12-13","conditions":"Liver Lymphoma, Mantle Cell Lymphoma","enrollment":360},{"nctId":"NCT03516617","phase":"PHASE2","title":"Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-09-10","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":120},{"nctId":"NCT05583149","phase":"PHASE2","title":"Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Patrick C. Johnson, MD","startDate":"2023-03-01","conditions":"Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL","enrollment":28},{"nctId":"NCT04855695","phase":"PHASE1, PHASE2","title":"Avo In R/R And Previously Untreated MCL","status":"RECRUITING","sponsor":"Austin I Kim","startDate":"2021-07-02","conditions":"Mantle Cell Lymphoma, Refractory Lymphoma","enrollment":72},{"nctId":"NCT04604067","phase":"PHASE2","title":"Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2021-06-25","conditions":"Diffuse Large B-cell Lymphoma","enrollment":260},{"nctId":"NCT05952024","phase":"PHASE2","title":"Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-07-16","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":80},{"nctId":"NCT03162536","phase":"PHASE1, PHASE2","title":"A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)","status":"ACTIVE_NOT_RECRUITING","sponsor":"ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)","startDate":"2017-06-26","conditions":"Lymphoma, B-Cell, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia","enrollment":190},{"nctId":"NCT02475681","phase":"PHASE3","title":"Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2015-06-26","conditions":"Chronic Lymphocytic Leukemia","enrollment":535},{"nctId":"NCT04626791","phase":"PHASE2","title":"Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Academic and Community Cancer Research United","startDate":"2021-08-03","conditions":"Mantle Cell Lymphoma","enrollment":45},{"nctId":"NCT03736616","phase":"PHASE2","title":"Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL","status":"UNKNOWN","sponsor":"Swedish Medical Center","startDate":"2019-08-16","conditions":"Diffuse Large B Cell Lymphoma","enrollment":47},{"nctId":"NCT05140096","phase":"PHASE1","title":"A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) When Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult Participants","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2020-01-03","conditions":"Healthy Volunteers","enrollment":30},{"nctId":"NCT04867980","phase":"PHASE1","title":"A Study to Evaluate the Effect of ACP-196 on the Heart Rate-corrected QT Interval in Healthy Adult Participants","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2016-04-01","conditions":"Healthy Volunteers","enrollment":48},{"nctId":"NCT04488016","phase":"PHASE1","title":"A Study to Evaluate Relative Bioavailability, Proton Pump Inhibitor (PPI) (Rabeprazole) Effect, Food Effect and Particle Size Effect of New Acalabrutinib Tablet in Healthy Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-06-24","conditions":"Bioavailability, B-cell Lymphoid Cancer","enrollment":54},{"nctId":"NCT04564040","phase":"PHASE1","title":"A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-10-12","conditions":"Mantle Cell Lymphoma, COVID-19","enrollment":20},{"nctId":"NCT04435483","phase":"PHASE1","title":"A Study of Acalabrutinib Suspension to Evaluate Relative Bioavailability and Proton-pump Inhibitor Effect in Healthy Volunteers","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-05-22","conditions":"Pharmacokinetics, Bioavailability","enrollment":39}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AT and Pariet® (raberprazole)"],"phase":"phase_1","status":"active","brandName":"Acalabrutinib Treatment C","genericName":"Acalabrutinib Treatment C","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BTK inhibitor Used for Chronic lymphocytic leukemia, Mantle cell lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}